Collaboration - September 22, 2014
Sobi collaborates with Biogen Idec
Sobi is planning to include a new preclinical hemophilia project in an agreement with Biogen Idec. Accodring to an announcement, Sobi has elected to add the preclinical rFVIIIFc-XTEN-vWF fusion molecule to the company’s collaboration with Biogen Idec. The XTEN technology is proprietary to Amunix Operating, Inc.. Biogen Idec and Amunix signed a worldwide license agreement […]
Business Award - July 1, 2014
Sobi receives award
Sobi has been awarded as company of the year at the European Mediscience Awards 2014. The award is given to companies that has achieved recognition from analysts and investors on how the company is run, its financial stability and growth and to companies with a clear strategy on the ambitions regarding its financial, ethical and […]
Drug Development Pharma - June 25, 2014
Sobi files for EU approval of Xiapex for Peyronies disease
Sobi has filed for an extension of the label for Xiapex with the European Medicines Agency (EMA) to include the indication of Peyronie’s disease. The filing is based on positive safety and efficacy outcome data from two double-blind placebo-controlled studies, IMPRESS I and II (The Investigation for Maximal Peyronie’s Reduction Efficacy and Safety Studies) which […]
Clinical Trials - April 11, 2014
Sobi and Biogen announce positive results from paediatric study
Biogen Idec and Sobi announce positive top-line efficacy and safety results from a phase-3 paediatric study of investigational therapy Eloctate for haemophilia A.
Agreement - April 4, 2014
Sobi enters partnership with Tigenix
Sobi has acquired the licencing rights to market and distribute Tigenix’s product ChondroCelect.
Drug Development Pharma - April 1, 2014
FDA approves Sobi’s Alprolix
Sobi’s partner Biogen Idec have announced that the US Food and Drug Administration (FDA) has approved Alprolix.
